ARDX– Ardelyx, Inc is a clinical stage bio-pharmaceutical company which develops therapeutic drugs for the treatment of Gastro-Intestinal and Cardio – Renal diseases. ARDX was given a “Buy”rating from Ladenburg Thalmann, and may be bullish today.
ARDX – Ardelyx, Inc.
|Fundamentals||Previously closed at||7.77|
|Analysts opinion||Out of the 4 wall street analysts covering the stock, all 4 have given this stock a “Strong Buy” rating. For the most recent quarter, Ardelyx reported a surprise factor of 12.16%. The Analyst consensus price target for the stock is $19.|
|Anapanor, Ardelyx’s lead investigational drug expected to cure IBS-C (Irritable bowel syndrome with constipation) is currently under Phase 3 clinical studies. According to study, there are approx. 4.4 million Americans, 6.6 million Europeans, and 3.4 Japanese suffering from IBS-C- a huge potential market for Anapanor.|
|Sentiments||One of Ardelyx’s Director Gordon Ringold purchased 15,000 shares of the firm at $7.64 – $7.86 per share. This may cause further bullish investor sentiments|
|Social Media Pulse||The stock has 100% lower chatter than usual.|
TGT – Target Corporation is a retailer, which provides everyday essentials, and fashionable products at discounted prices through its stores, online and through mobile applications.
TGT – Target Corporation
|Fundamentals||Previously closed at||82.36|
|Analyst opinion||Target Corporation has great fundamentals with a forward P/E of 14.26, lower than the S&P 500’s 17. It has seen a growth of 12% Year-to-date, despite which, Barclay’s has downgraded TGT to “Sell” and cut its target price to $70. According to Barclay’s retail sector may see hard times. There seems to be operating margin deterioration at specific type of retailers, like home furnishings and broadline retailers – and at some point, when there is an economic downturn, only the best ones may survive.|
|Most analysts disagree with the “sell” rating, and maintain a positive outlook for TGT. Analysts believe that this stock may see support at $84, and bullish afterward.|
|Sentiments||Due to Barclay’s downgrade, the stock may see some volatility today, but due to its strong fundamentals, it is expected to be bullish in the medium – long term.|
|Social Media Pulse||The stock has 100% higher social chatter than usual.|
Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See http://stockal.com/legalities/